1119 related articles for article (PubMed ID: 34503440)
1. Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
Duarte RRR; Copertino DC; Iñiguez LP; Marston JL; Bram Y; Han Y; Schwartz RE; Chen S; Nixon DF; Powell TR
Mol Med; 2021 Sep; 27(1):105. PubMed ID: 34503440
[TBL] [Abstract][Full Text] [Related]
2. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.
Han Y; Duan X; Yang L; Nilsson-Payant BE; Wang P; Duan F; Tang X; Yaron TM; Zhang T; Uhl S; Bram Y; Richardson C; Zhu J; Zhao Z; Redmond D; Houghton S; Nguyen DT; Xu D; Wang X; Jessurun J; Borczuk A; Huang Y; Johnson JL; Liu Y; Xiang J; Wang H; Cantley LC; tenOever BR; Ho DD; Pan FC; Evans T; Chen HJ; Schwartz RE; Chen S
Nature; 2021 Jan; 589(7841):270-275. PubMed ID: 33116299
[TBL] [Abstract][Full Text] [Related]
3. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
5. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704
[TBL] [Abstract][Full Text] [Related]
6.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
7. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
8. Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M
Abosheasha MA; El-Gowily AH
Drug Dev Res; 2021 Apr; 82(2):217-229. PubMed ID: 32984987
[TBL] [Abstract][Full Text] [Related]
9. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
10. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
11. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
Kandeel M; Al-Nazawi M
Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
[TBL] [Abstract][Full Text] [Related]
12. Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
Yang L; Pei RJ; Li H; Ma XN; Zhou Y; Zhu FH; He PL; Tang W; Zhang YC; Xiong J; Xiao SQ; Tong XK; Zhang B; Zuo JP
Acta Pharmacol Sin; 2021 Aug; 42(8):1347-1353. PubMed ID: 33116249
[TBL] [Abstract][Full Text] [Related]
13. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
14. Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.
Egilmezer E; Rawlinson WD
Rev Med Virol; 2021 Nov; 31(6):e2227. PubMed ID: 33763936
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
16. Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
Farhat N; Khan AU
J Mol Model; 2021 Oct; 27(11):312. PubMed ID: 34601658
[TBL] [Abstract][Full Text] [Related]
17. In Silico Screening and Testing of FDA-Approved Small Molecules to Block SARS-CoV-2 Entry to the Host Cell by Inhibiting Spike Protein Cleavage.
Ozdemir ES; Le HH; Yildirim A; Ranganathan SV
Viruses; 2022 May; 14(6):. PubMed ID: 35746605
[TBL] [Abstract][Full Text] [Related]
18. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
[TBL] [Abstract][Full Text] [Related]
19. Precision therapeutic targets for COVID-19.
Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
[TBL] [Abstract][Full Text] [Related]
20. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
Dhankhar P; Dalal V; Kumar V
J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
